Figure 7.
The benefits of ICI score in predicting immunotherapy. (A–H) Scatterplot and boxplot of PD1 (A, B), PD-L1 (C, D), PD-L2 (E, F), and CTLA4 (G, H) expression in risk scores. (I–L) IPS values of patients categorized according to ICI score of four subtypes [IPS-CTLA4-neg-PD1-neg (I), IPS-CTLA4-neg-PD1-pos (J), IPS-CTLA4-pos-PD1-pos (K), IPS-CTLA4-pos-PD1-neg (L)]. (M, N) The IC50 of cisplatin and paclitaxel in low and high ICI groups.
